Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
Rev Esp Quimioter. 2023 Dec;36(6):562-583. doi: 10.37201/req/115.2023. Epub 2023 Nov 2.
This document is the result of the deliberations of the Committee on Emerging Pathogens and COVID-19 of the Illustrious Official College of Physicians of Madrid (ICOMEM) regarding the current situation of tuberculosis, particularly in Spain. We have reviewed aspects such as the evolution of its incidence, the populations currently most exposed and the health care circuits for the care of these patients in Spain. We have also discussed latent tuberculosis, the reality of extrapulmonary disease in the XXI century and the means available in daily practice for the diagnosis of both latent and active forms. The contribution of molecular biology, which has changed the perspective of this disease, was another topic of discussion. The paper tries to put into perspective both the classical drugs and their resistance figures and the availability and indications of the new ones. In addition, the reality of direct observation in the administration of antituberculosis drugs has been discussed. All this revolution is making it possible to shorten the treatment time for tuberculosis, a subject that has also been reviewed. If everything is done well, the risk of relapse of tuberculosis is small but it exists. On the other hand, many special situations have been discussed in this paper, such as tuberculosis in pediatric age and tuberculosis as a cause for concern in surgery and intensive care. The status of the BCG vaccine and its present indications as well as the future of new vaccines to achieve the old dream of eradicating this disease have been discussed. Finally, the ethical and medicolegal implications of this disease are not a minor issue and our situation in this regard has been reviewed.
本文件是马德里杰出医师官学院新兴病原体和 COVID-19 委员会审议的结果,涉及结核病的现状,特别是在西班牙。我们审查了其发病率的演变、目前面临最大风险的人群以及西班牙对这些患者的医疗保健流程。我们还讨论了潜伏性结核病、21 世纪的肺外疾病的现实以及在日常实践中用于诊断潜伏性和活动性形式的现有手段。分子生物学的贡献改变了对这种疾病的看法,这是另一个讨论的话题。本文试图从经典药物及其耐药数据的角度,以及新型药物的可用性和适应症的角度来看待这一问题。此外,还讨论了在抗结核药物管理中直接观察的现实情况。所有这些变革正在使结核病的治疗时间缩短,这也是一个被审查的主题。如果一切都做得好,结核病复发的风险很小,但确实存在。另一方面,本文还讨论了许多特殊情况,如儿科年龄的结核病以及手术和重症监护中令人关注的结核病。BCG 疫苗的现状及其目前的适应症以及实现消除这种疾病这一古老梦想的新型疫苗的未来也进行了讨论。最后,这种疾病的伦理和医疗法律影响不容忽视,我们在这方面的情况也进行了审查。